Cover Image
市場調查報告書

全球生物製藥 (生物醫藥品) API (原料藥) 製造服務業和市場預測 2016年∼2026年

Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine

出版商 Visiongain Ltd 商品編碼 333982
出版日期 內容資訊 英文 238 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球生物製藥 (生物醫藥品) API (原料藥) 製造服務業和市場預測 2016年∼2026年 Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine
出版日期: 2016年08月15日 內容資訊: 英文 238 Pages
簡介

Title:全球生物製藥 (生物醫藥品) API (原料藥) 製造服務業和市場預測 2016年∼2026年:哺乳類細胞培養·微生物發酵·人體生長荷爾蒙·胰島素·干擾素·單株抗體、疫苗

本報告提供全球生物製藥的API (原料藥) 受託製造服務市場相關調查,彙整全球外包生技藥品API市場·子市場收益,主要國家市場分析,生技藥品API的開發·製造的影響的課題與機會,及主要企業簡介等資訊,為您概述為以下內容。

第1章 調查概要

第2章 簡介:生物科技API製造服務

  • 生物科技API製造服務
  • 生物科技API製造的課題
  • 外包:生物科技API製造服務的通用趨勢
  • 生物科技API製造服務市場未來趨勢
  • 詞彙表

第3章 生物科技API製造服務:全球市場的展望·預測

  • 生物科技API受託製造服務市場業績
  • 生物科技API製造服務市場促進要素·阻礙要素
  • 外包生物科技API服務的展望:需求擴大

第4章 生物科技API製造服務的子市場:全球市場的展望·預測

  • 生物科技API製造服務業的子市場
    • 哺乳類細胞培養市場
    • 哺乳類細胞培養市場預測
    • 預計ADS及新一代抗體將促進成長
    • 微生物發酵市場
    • 微生物發酵市場預測
    • 其他API表現系統仍在開發中
  • 本章的摘要:市場Plus成長

第5章 生物科技API製造:主要的生技藥品的API受託製造部門的展望

  • 抗體療法:最大的生技藥品API受託製造部門的簡介
  • API疫苗受託製造:對CMO而言有潛力的機會
  • 胰島素療法市場簡介及胰島素療法的API受託製造市場展望
  • 干擾素療法市場簡介及干擾素療法的API受託製造市場展望
  • 生長激素市場簡介及生長激素的API受託製造市場展望
  • 本章摘要:主要生技藥品產品的外包

第6章 生物科技API受託製造服務的主要國家市場

  • 全球生物科技API受託製造服務市場明細
  • 歐洲的生物科技API受託製造
  • 本章的摘要

第7章 生物科技API受託製造服務市場上主要CMO

  • 4家公司推動市場
  • 主要企業:生產能力別
  • FDA除去生技仿製藥市場障礙
  • Boehringer Ingelheim BioXcellence
  • Celltrion:亞洲的生技藥品領導者
  • DSM生技藥品:策略性擴大生產能力
  • Lonza擁有全球最大的細胞培養能力
  • 其他注目的市場參與企業
  • 營運CMO部門的主要生物製藥公司
  • Teva:生技藥品市場上的未來企業
  • Catalent透過合作來提供新的平台
  • 本章的摘要:主要企業

第8章 生物科技API製造服務市場產業趨勢:定性分析

  • SWOT分析
  • 機會
  • 威脅
  • STEP分析
  • 生技藥品的開發趨勢
  • 生物科技API製造服務業相關法規及影響
  • 本章摘要:生物科技API受託製造產業趨勢

第9章 調查採訪

第10章 結論

  • 生物科技API受託製造服務市場
  • 生物科技API受託製造服務市場展望
  • 市場成長預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0137

Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2015 to 2026 for the biotech API manufacturing services market, as well as for therapeutic applications.

How this 238 page report delivers:

  • Provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:
    • Mammalian cell culture
    • Microbial fermentation
    • Other expression platforms
  • Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:
    • Monoclonal antibody (mAb) therapies
    • Vaccines
    • Insulin therapies
    • Interferon therapies
    • Growth hormones
  • Find forecasts of the leading therapeutic and national markets from 2015 to 2026:
    • The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
    • The US
    • Japan
    • Switzerland
    • Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.
  • Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
    • Boehringer Ingelheim BioXcellence
    • Celltrion
    • DSM Biologics
    • Lonza
    • Samsung BioLogics
    • Cytovance Biologics
    • Fujifilm Diosynth Biotechnologies
    • Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.
  • Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2016, as well as predicted developments for the period to 2026.
  • Read expert opinions from other authorities on the biotech API manufacturing industry.
  • Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2016. The report also contains SWOT and STEP analysis of the industry and market.
  • Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.

How This Report Delivers: Chapter Summary

This updated study provides an overview of the subject along with qualitative and quantitative analyses of the biotech API manufacturing services market. This report contains expert opinions from industry participants. In more detail, the chapters of this report contain the following information:

Chapter 1 forms a report overview.

Chapter 2 defines the biotech API manufacturing services market and provides an introduction to that industry.

Chapter 3 quantitatively assesses the world market for biotech API manufacturing services revenues. The chapter provides an estimate for the size of the market in 2015 and forecasts revenues for the period 2015-2026. Visiongain discusses the main drivers and restraints on the market for a 10-year forecast period.

Chapter 4 provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:

  • Mammalian cell culture
  • Microbial fermentation
  • Other expression platforms.

For the leading submarkets, we analyse commercial drivers and restraints, as well as forecasting revenues to 2026.

Chapter 5 provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:

  • Monoclonal antibody (mAb) therapies
  • Vaccines
  • Insulin therapies
  • Interferon therapies
  • Growth hormones.

Chapter 6 forecasts the leading national submarkets for biotech API manufacturing services, for the period 2015-2026. That section also provides quantitative analysis. The chapter offers a regional breakdown of the market by market share, and also discusses developments and future expectations for each main national submarket. National submarkets forecasted in this chapter are these:

  • The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
  • The US
  • Japan
  • Switzerland
  • Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.

Chapter 7 profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:

  • Boehringer Ingelheim BioXcellence
  • Celltrion
  • DSM Biologics
  • Lonza
  • Samsung BioLogics
  • Cytovance Biologics
  • Fujifilm Diosynth Biotechnologies
  • Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.

Chapter 8 provides qualitative analysis of the biotech API manufacturing services market from 2015. That chapter identifies main strengths and weaknesses of the market, as well as opportunities and threats facing CMOs to 2026. Social, technological, economic and political (STEP) factors affecting market growth are also discussed. Industry trends and regulatory developments affecting the market are discussed.

Chapter 9 provides transcripts of interviews conducted by visiongain with other authorities. For this report, visiongain interviewed the following authorities on the CMO industry:

  • Steve Bagshaw, CEO, Fujifilm Diosynth Biotechnologies, UK.
  • Jon S. Gingrich, Manager of Business Development, Avid Bioservices Inc., US.

Chapter 10 summarises the report, highlighting conclusions from visiongain's research and analysis.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Contract Biotech API Manufacturing: World Market Review 2016
  • 1.2. Benefits of this Report
    • 1.2.1. How This Report Delivers
    • 1.2.2. Main Questions Answered by This Analytical Report
  • 1.3. Who is This Report For?
  • 1.4. Methods of the Study
  • 1.5. Frequently Asked Questions (FAQ)
  • 1.6. Some Associated Reports
  • 1.7. About Visiongain

2. Introduction to Biotech API Manufacturing Services

  • 2.1. What are Biotech API Manufacturing Services?
    • 2.1.1. Producing Biotech API: An Overview of the Manufacturing Process
    • 2.1.2. Defining the Biotech API Manufacturing Market
    • 2.1.3. Differing Expression Systems to Manufacture APIs
  • 2.2. Challenges in Manufacturing Biotech API
  • 2.3. Outsourcing: A Common Trend in Biotech API Manufacturing Services
  • 2.4. Future Trends for the Biotech API Manufacturing Services Market
  • 2.5. Glossary

3. Biotech API Manufacturing Services: World Market Outlook and Forecast 2016-2026

  • 3.1. The Contract Biotech API Manufacturing Services Market Performance, 2016
    • 3.1.1. Contract Biotech API Manufacturing Services: Forecast 2015-2026
  • 3.2. Drivers and Restraints in the Biotech API Manufacturing Services Market
    • 3.2.1. Important Drivers in the Biotech API Manufacturing Services Market for the Coming Decade
      • 3.2.1.1. The Ageing Population is a Driver for Growth
      • 3.2.1.2. The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
      • 3.2.1.3. Outsourcing as a Driver for Growth
      • 3.2.1.4. Opportunities from the Long Pipeline Will Drive Growth
      • 3.2.1.5. Increased Investment in Orphan Drugs from Companies
      • 3.2.1.6. Emerging Markets Will Grow and Influence the Market
      • 3.2.1.7. Technological Changes: Single-Use Technology Will Become Essential in the Next 10. Years
    • 3.2.2. Restraints on Growth in the Biotech API Manufacturing Services Market
      • 3.2.2.1. Pricing Pressures Will Limit Market Growth
      • 3.2.2.2. Regulatory Restrictions Will Increase
      • 3.2.2.3. Overcapacity Will Be Adverse to Market Growth for CMOs
      • 3.2.2.4. Complexity of API Production is a Challenge
  • 3.3. Outlook for the Outsourced Biotech API Services: Increased Demand

4. Biotech API Manufacturing Services Submarkets: World Market Outlook and Forecasts 2016-2026

  • 4.1. Submarkets for the Biotech API Manufacturing Services Industry
    • 4.1.1. The Mammalian Cell Culture Submarket
    • 4.1.2. The Mammalian Cell Culture Submarket Forecast 2015-2026
    • 4.1.3. ADCs and Next-Generation Antibodies Will Drive Growth 2015-2026
    • 4.1.4. The Microbial Fermentation Submarket
    • 4.1.5. The Microbial Fermentation Submarket Forecast 2015-2026
      • 4.1.5.1. Increase in Demand for Insulin Will Drive Growth 2015-2026
    • 4.1.6. Other APIs Expression Systems Are Still in Development
      • 4.1.6.1. Plant-Made Pharmaceuticals
      • 4.1.6.2. Yeast Cell Expression Systems
      • 4.1.6.3. Insect Cell Expression Systems
      • 4.1.6.4. Other Expression Systems Submarket Forecast 2015-2026
  • 4.2. Chapter Summary: Positive Growth for the Market

5. Biotech API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors: 2015-2026

  • 5.1. Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
    • 5.1.1. Contract API Monoclonal Antibody Manufacturing Forecast 2015-2026
    • 5.1.2. Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
  • 5.2. Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
    • 5.2.1. Contract API Vaccine Market: Outlook and Forecast 2015-2026
    • 5.2.2. Challenges in Manufacturing Vaccines
  • 5.3. Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
    • 5.3.1. Contract API Insulin Analogues Forecast 2015-2026
    • 5.3.2. Insulin Analogues: In-House Production Restrains Contract API Insulin Therapies Market Growth
    • 5.3.3. Development Trends in the Contract API Insulin Market to 2026
  • 5.4. Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
    • 5.4.1. Contract API Interferon Market Forecast 2015-2026
    • 5.4.2. Unlikely to be Opportunities in the Contract API Interferon Market
  • 5.5. Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
    • 5.5.1. Contract API Growth Hormone Market Forecast 2015 to 2026
    • 5.5.2. Most Manufacturing is In-House for Growth Hormone Production
    • 5.5.3. Long-Acting Therapies Provide Opportunity for Outsourcing
  • 5.6. Chapter Summary: Outsourcing for Key Biological Products 2015-2026

6. Leading National Markets for Contract Biotech API Manufacturing Services 2015-2026

  • 6.1. Regional Breakdown of the World Biotech API Manufacturing Services Market
    • 6.1.1. US and EU Dominate Growth for Leading National Submarkets 2015-2026
    • 6.1.2. National Revenue Shares by 2026: Emerging Market Growth
  • 6.2. Contract Biotech API Manufacturing in EU Market 2015-2026
    • 6.2.1. Strong Growth for the EU Revenue Forecasts 2015-2026
    • 6.2.2. Forecasts for Switzerland and Leading EU National Revenues 2015-2026
      • 6.2.2.1. Germany Leads the EU Biotech Market with Strong Growth
      • 6.2.2.2. UK: Strong Research Sector Will Drive Market Growth
      • 6.2.2.3. France: Strong Vaccine Development Industry
      • 6.2.2.4. Switzerland: Headquarters for Leading Companies
        • 6.2.2.4.1. Switzerland: Headquarters for Leading Companies
      • 6.2.2.5. Spain: Numerous Biotech Companies
      • 6.2.2.6. Italy: Outlook and Forecast 2015-2026
    • 6.2.3. US: A Market Leader in Biotech API Manufacturing
    • 6.2.4. Japan: A Less Mature Contract Manufacturing Market
    • 6.2.5. BRIC Market: Outlook and Forecasts for Emerging Markets 2015- 2026
      • 6.2.5.1. Emerging Nations May Develop a Presence in the Biologics Market
      • 6.2.5.2. Increased Demand for Biosimilars and Biological Drugs 2015-2026
      • 6.2.5.3. China is Poised for Growth: Forecast for 2015-2026
      • 6.2.5.4. India Offers a Lower-Cost Advantage for Biotech API Manufacturing Services: Forecast 2015-2026
      • 6.2.5.5. Brazilian and Russian Governments Promoting Domestic Biotech Development
      • 6.2.5.6. Russian Biotech API Manufacturing Services Forecast: 2015-2026
      • 6.2.5.7. Brazilian Biotech API Manufacturing Services Forecast: 2015-2026
    • 6.2.6. South Korea: Market Forecast, 2015-2026
      • 6.2.6.1. Leading CMOs Celltrion and Samsung BioLogics Drive the Market
    • 6.2.7. Singapore: Market Forecast, 2015-2026
  • 6.3. Summary of Chapter: Outlook for Leading National Submarkets 2015-2026

7. Leading CMOs in the Biotech API Manufacturing Services Market 2016

  • 7.1. Four Companies Led the Market in 2015
  • 7.2. Leading Companies by Capacity
    • 7.2.1. Small-Scale Biopharmaceutical Manufacturing is a Common Trend
    • 7.2.2. Barriers to Market Entry 2015-2026
      • 7.2.2.1. The High Cost of Facilities: Acquisition as a Cheaper Alternative
  • 7.3. FDA Opens Barriers for the Biosimilars Market
  • 7.4. Boehringer Ingelheim BioXcellence
    • 7.4.1. Strategic Outlook: Expanding into the Asian Market
  • 7.5. Celltrion: Biologics Leader in Asia
    • 7.5.1. Celltrion: Likely Target for Mergers and Acquisitions?
  • 7.6. DSM Biologics: Strategically Increasing Capacity
  • 7.7. Lonza Has the Largest Worldwide Cell Culture Capacity
    • 7.7.1. Lonza: Biopharmaceutical Core Competency as a Strategy for Growth
  • 7.8. Other Market Players of Interest in 2016
    • 7.8.1. Samsung BioLogics: Focusing on Biosimilars
    • 7.8.2. Cytovance Biologics: Plans to Expand
    • 7.8.3. Fujifilm Diosynth Biotechnologies
      • 7.8.3.1. Facility and Service Expansion for the Future
  • 7.9. Leading Biopharma Companies Operate CMO Divisions
    • 7.9.1. AbbVie Contract Manufacturing: Strength through Acquisition
    • 7.9.2. GSK Biopharmaceuticals
    • 7.9.3. Sandoz: Expertise in Biologics and Biosimilars
    • 7.9.4. Rentschler Biotechnologie: Recent Expansions
  • 7.10. Teva: A Future Player in the Biologics Market
  • 7.11. Catalent Offers a New Platform through Partnership
  • 7.12. Chapter Summary: Leading Companies 2015-2026

8. Biotech API Manufacturing Services Market Industry Trends 2015-2026: Qualitative Analysis

  • 8.1. SWOT Analysis: Strengths and Weaknesses of the Biotech API Manufacturing Services Market 2016
    • 8.1.1. Biopharmaceutical Demand for Outsourcing is Increasing
    • 8.1.2. A Fragmented Market with a Costly and Difficult Manufacturing Process
  • 8.2. Opportunities for the Biotech API Manufacturing Services Market 2015-2026
  • 8.3. Threats for the Biotech API Manufacturing Services Market 2015-2026
  • 8.4. STEP Analysis of the Biotech API Manufacturing Services Market
    • 8.4.1. Social Factors: Drug Pricing Pressures to Meet Demand for an Increasing Ageing Population
    • 8.4.2. Technological Factors: Advances Will Drive Growth
      • 8.4.2.1. Single-Use Technology: A Vital Trend for the Future
    • 8.4.3. Economic Factors: The High Cost of Manufacturing Will Lead to Outsourcing
    • 8.4.4. Political Factors: Regulatory Requirements Need to Be Met
  • 8.5. Trends in Biological Drug Development 2015-2026
    • 8.5.1. Biosimilars Will Be an Important Opportunity for CMOs
    • 8.5.2. CMOs are Investing in Next-Generation Antibody Development
    • 8.5.3. Orphan Drugs and Personalised Medicine: Trend for Smaller Batches
    • 8.5.4. Outlook for Single-Use Technologies in Biotech API Manufacturing 2015-2026
      • 8.5.4.1. Future Direction: Single-Use Systems Will be Essential
    • 8.5.5. Outsourcing Trends for Biotech API Manufacturing 2015-2026
      • 8.5.5.1. Biopharma Companies Continue to Invest in In-House Facilities
      • 8.5.5.2. Off-shoring Biotech API Manufacturing to Emerging Markets: Not a Trend for this Decade?
      • 8.5.5.3. Overcapacity is a Risk for the Biotech CMO Industry
      • 8.5.5.4. Future Trends: Strategic Partnering
      • 8.5.5.5. Alternative Expression Methods
  • 8.6. Regulations and Effects on the Biotech API Manufacturing Services Industry
    • 8.6.1. Effect on the Emerging Biotech API Manufacturing Services Market 2015-2026
    • 8.6.2. Regulations in Other Countries in the Biotech API Market
  • 8.7. Chapter Summary: Industry Trends for Contract Biotech API Manufacturing to 2026

9. Research Interviews

  • 9.1. Interview with Mr Steve Bagshaw, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies (Fujifilm)
    • 9.1.1. Novel Expression Platforms
    • 9.1.2. Expanding Manufacturing Capacity
    • 9.1.3. Acquisition of KalonBiotherapeutics - Effects on Business?
    • 9.1.4. Over-capacity - A Realistic Threat to API Manufacturing CMOS?
    • 9.1.5. Future Opportunities for the API Manufacturing CMO Market
  • 9.2. Interview with Mr Jon S. Gingrich, Manager, Business Development, Avid Bioservices Inc., California, USA
    • 9.2.1. Avid Bioservices
    • 9.2.2. The Influence of Biosimilars on the Current Biotech API Manufacturing Services Market for CMOs
    • 9.2.3. Competition in the US Biotech API Manufacturing Services Market
    • 9.2.4. The Challenges of API Manufacturing
    • 9.2.5. Avid Bioservices Strategies for Growth in the Biotech API Manufacturing Services Market

10. Conclusions

  • 10.1. The Contract Biotech API Manufacturing Services Market
  • 10.2. Outlook for the Biotech API Manufacturing Services Market
    • 10.2.1. Mammalian Cell Culture is the Leading Expression Platform for Outsourced Biotech API Manufacturing
    • 10.2.2. The US and EU Markets Lead for the Global Biotech API Manufacturing Services Market in 2015
    • 10.2.3. Single-Use Technology Will Become Indispensable for Success in the Market
  • 10.3. Growth in the Market 2015-2026
    • 10.3.1. The Future of the Biotech API Manufacturing Services Marketplace
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: Biological Drug API Manufacturing Services Submarkets 2016
  • Figure 2.1: Steps for Biological Drug Manufacturing, 2016
  • Figure 2.2: Contract API Manufacturing: Market Shares by Sector (%), 2015
  • Figure 2.3: Future Trends in the Biotech API Manufacturing Market, 2016-2026
  • Figure 3.1: Contract Biotech API Manufacturing Services Market: Revenue Forecast ($bn), AGR (%), 2016-2026
  • Figure 3.2: Contract Biotech API Manufacturing: Market Drivers, 2016-2026
  • Figure 3.3: Contract Biotech API Manufacturing: Market Restraints, 2016-2026
  • Figure 4.1: Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2015
  • Figure 4.2: Mammalian Cell Culture Submarket Forecast, Revenue ($bn), AGR(%), 2015-2026
  • Figure 4.3: Mammalian Cell Culture Submarket: Drivers and Restraints, 2015-2026
  • Figure 4.4: Microbial Fermentation Submarket Forecast($bn), AGR (%), 2015-2026
  • Figure 4.5: Microbial Fermentation Submarket: Drivers and Restraints, 2016
  • Figure 4.6: Forecast for Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2015-2020
  • Figure 4.6.1: Forecast for Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2021-2026
  • Figure 5.1: Leading Contract API Biological Drug by Sector, 2015
  • Figure 5.2: Monoclonal Antibody Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
  • Figure 5.3: Vaccines Market: Contract API Revenues Forecast ($bn), AGR(%) 2015-2026
  • Figure 5.3.1: Comparison between biomanufacturing platforms for Vaccine production: VLP
  • Figure 5.4: Insulin Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
  • Figure 5.5: Interferon Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
  • Figure 5.6: Growth Hormones Market: Contract API Revenues Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.1: Contract Biotech API Manufacturing: Market Shares by Region (%), 2016: Market Shares by Region (%), 2014
  • Figure 6.2: Contract Biotech API Manufacturing: Market Shares by Region (%) 2020
  • Figure 6.3: Contract Biotech API Manufacturing: Market Shares by Region (%) 2025
  • Figure 6.4: EU and Switzerland Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.5: EU Contract Biotech API Manufacturing: Leading National Revenue Shares (%), 2015
  • Figure 6.6: German Contract Biotech API Manufacturing Revenue Forecast ($bn), 2015-2026
  • Figure 6.7: UK Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.8: French Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.9: Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.10: Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.11: Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.12: US Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.13: Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.14: Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), AGR (%), 2015 -2026
  • Figure 6.15: Biologics Market: BRIC Revenue Shares (%), 2015
  • Figure 6.16: Biologics Market: China Revenue Shares (%), AGR (%), 2016
  • Figure 6.17: Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.18: Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.19: Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.20: South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 6.21: Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 7.1: Leading Biotech API CMOs: Mammalian Cell Culture Manufacturing Scale, 2015
  • Figure 7.2: Leading Biotech API CMOs: Microbial Fermentation Manufacturing Scale, 2015
  • Figure 7.3: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2013-2015
  • Figure 7.4: Celltrion: Revenue ($bn), 2009-2015
  • Figure 7.5: DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), 2011-2015
  • Figure 7.6: Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), 2009-2015
  • Figure 8.1: Biosimilars Market Revenue Forecast ($bn), AGR (%), 2015-2026
  • Figure 10.1: Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2016 - 2026
  • Figure 10.2: Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2016, 2018, 2020, 2022, 2024 and 2026

List of Tables

  • Table 1.1: Redacted Submarket Forecast : Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2015-2026
  • Table 2.1: Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2015
  • Table 3.1: Contract Biotech API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 3.1.1: Contract Biotech API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.1: Contract Biotech API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), AGR(%), CAGR(%), 2015-2020
  • Table 4.1.1: Contract Biotech API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), AGR(%), CAGR(%), 2020-2026
  • Table 4.2: ADC Pipeline 2016
  • Table 4.3: Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), AGR(%), CAGR(%), 2015-2020
  • Table 4.3.1: Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), AGR(%), CAGR(%), 2021-2026
  • Table 4.4: Selected CMOs Investing in Biological API Manufacturing Capacity, 2016
  • Table 4.5: Microbial Fermentation: API Submarket Revenue Forecast ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.5.1: Microbial Fermentation: API Submarket Revenue Forecast ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.6: Other Expression Systems Submarket Two Year Forecast Revenues ($bn), AGR (%), 2015-2026
  • Table 5.1: Top Ten Best-Selling Drugs in 2015: Revenue ($bn)
  • Table 5.2: Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Therapeutic Area, 2015-2020
  • Table 5.3: Leading Contract API Biological Drug Revenue Forecasts ($bn) AGR (%), CAGR (%), by Therapeutic Area, 2020-2026
  • Table 5.4: Monoclonal Antibody Types and Sources
  • Table 5.5: Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 5.5.1: Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 5.6: The Four Classes of Next- Generation Antibody Therapies
  • Table 5.7: Vaccines Market: Contract API Revenue Forecast ($bn), GAGR (%), AGR (%) 2015-2020
  • Table 5.7.1: Vaccines Market: Contract API Revenue Forecast ($bn), GAGR (%), AGR (%) 2020-2026
  • Table 5.8: Insulin Therapies Market: Contract API Revenue Forecast ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.8.1: Insulin Therapies Market: Contract API Revenue Forecast ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.9: Interferon Therapies Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 5.9.1: Interferon Therapies Market: Contract API Revenue Forecast ($bn), ), CAGR (%), AGR (%), 2020-2026
  • Table 5.10: Growth Hormones Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 5.10.1: Growth Hormones Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2020-2026
  • Table 5.11: Selected Long-Acting Growth Hormones in Development, 2016
  • Table 6.1: Contract Biotech API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2015
  • Table 6.2: Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.3.1: Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.4: Contract Biotech API Manufacturing Market: National Revenue Two Year Shares (%), 2016-2026
  • Table 6.5: EU and Switzerland Contract Biotech API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2015-2020
  • Table 6.5.1: EU and Switzerland Contract Biotech API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2021-2026
  • Table 6.6: EU and Switzerland Contract Biotech API Manufacturing: Revenues ($bn) and Shares (%) by Leading Country, 2015
  • Table 6.7: German Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2015-2026
  • Table 6.7.1: German Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2015-2026
  • Table 6.8: UK Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2015-2020
  • Table 6.8.1: UK Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2021-2026
  • Table 6.9: French Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2015-2020
  • Table 6.9.1: French Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2021-2026
  • Table 6.10: Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.10.1: Swiss Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.11: Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2015-2020
  • Table 6.11.1: Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2020-2026
  • Table 6.12: Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.12.1: Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.13: US Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.13.1: US Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.14: Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.14.1: Japanese Contract Biotech API Manufacturing Revenue Forecast, CAGR (%), AGR (%), ($bn),2021-2026
  • Table 6.15: Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.15.1: Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.16: BRIC Markets: API Revenues ($bn) and Market Shares (%), 2015
  • Table 6.17: Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.17.1: Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.18: Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%) 2015-2020
  • Table 6.18.1: Indian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.19: Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.19.1: Russian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.20: Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.20.1: Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.21: South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.21.1: South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 6.22: Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Tuas, 2015
  • Table 6.23: Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2015-2020
  • Table 6.23.1: Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2021-2026
  • Table 7.1: Leading Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
  • Table 7.2: Selected Other Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
  • Table 7.3: Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2015
  • Table 7.4: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2013-2015
  • Table 7.5: Celltrion: Revenue ($bn), CAGR (%), AGR (%), 2009-2015
  • Table 7.6: Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), CAGR (%), AGR (%), 2009-2015
  • Table 7.7: Lonza: New Biological Drug Sector Manufacturing Agreements, 2015
  • Table 7.8: Sandoz Biosimilar Pipelines: Selected Biosimilars, 2016
  • Table 8.1: Contract Biotech API Manufacturing Market: Strengths and Weaknesses, 2015-2016
  • Table 8.2: Contract Biotech API Manufacturing Market: Opportunities and Threats, 2015-2026
  • Table 8.3: Biotech API Manufacturing Services Market: STEP Analysis, 2016
  • Table 8.4: Selected EU-Approved Biosimilars: Manufacturers and Companies, 2015
  • Table 8.5: Approved Next-Generation Antibody Therapies, 2015
  • Table 10.1: Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2016, 2018, 2020, 2022, 2024 and 2026
  • Table 10.2: Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2016, 2018, 2020, 2022, 2024 and 2026

Companies Listed

  • 3P Biopharmaceuticals
  • AbbVie
  • AbbVie Contract Manufacturing (part of AbbVie)
  • Adocia
  • Ajinomoto Omnichem
  • Ambrx
  • Amgen
  • Aptuit
  • arGEN-X N.V.
  • AstraZeneca
  • Avid Bioservices (part of Peregrine Pharmaceuticals)
  • Bachem
  • Banner Life Sciences (part of DPx Holdings)
  • BaroFold
  • Baxter International
  • Bayer
  • Biocad
  • Bioceuticals Arzneimittel (part of Stada)
  • Biocon
  • Biogen Idec
  • Bioplanta
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)
  • Bristol-Myers Squibb
  • Calico Life Sciences
  • Carbogen Amcis
  • Catalent
  • Celltrion
  • Cinfa
  • CMC Biologics
  • Cytovance Biologics
  • DPx Fine Chemicals (part of DPx Holdings)
  • DPx Holdings
  • DSM Biologics (was part of Royal DSM, now part of DPx Holdings)
  • DSM Sinochem Pharmaceuticals (part of DPx Holdings)
  • Eisai
  • Eli Lilly
  • EMD Millipore (part of Merck)
  • European Medicines Agency (EMA)
  • Ferring Pharmaceuticals
  • Food and Drug Administration (US FDA)
  • Fujifilm
  • Fujifilm Diosynth Biotechnologies (part of Fujifilm)
  • Gallus Biopharmaceuticals (part of DPx Holdings)
  • GE Healthcare
  • Genentech (part of Roche)
  • Genmab
  • Genzyme (part of Sanofi)
  • Gilead Sciences
  • GlyTech
  • Granules
  • GSK
  • GSK Biopharmaceuticals (part of GSK)
  • Hexal (part of Novartis)
  • Hospira
  • Hospira One2One (part of Hospira)
  • Infinity Pharmaceuticals
  • International Diabetes Federation
  • Ipsen
  • Kalon Biotherapeutics (part of Fujifilm)
  • Korea Food and Drug Administration (KFDA)
  • Kyowa Hakko Kirin
  • Laureate Biopharma (part of DPx Holdings)
  • Lek Pharmaceuticals (Sandoz)
  • Lonza
  • Medice
  • Merck & Co.
  • Merck Biomanufacturing Network
  • Merck KGaA
  • Merck Millipore
  • Merck Serono
  • Millennium Pharmaceuticals
  • Millhouse LLC
  • Ministry for Food and Drug Safety [Korea]
  • Ministry of Health [Brazil]
  • Mitsubishi Gas Chemical Company
  • Mylan
  • Neopharm
  • Nikon
  • Norbitec
  • Nordmark Arzneimittel
  • Novartis
  • Novasep
  • Novo Nordisk
  • Nuron Biotech
  • Nycomed
  • Open Monoclonal Technology (OMT)
  • Opko Health
  • Patheon (part of DPx Holdings)
  • Patheon Biologics(part of DPx Holdings)
  • Peregrine Pharmaceuticals
  • Perrigo
  • Pfizer
  • Pharmacyclics
  • Pharmstandard
  • Phyton Biotech
  • Piramal Healthcare
  • Precision Biologics
  • Prolor Biotech
  • Quintiles
  • Recepta Biopharma
  • Redwood Bioscience (part of Catalent)
  • Relthy Laboratórios (part of Catalent)
  • Rentschler Biotechnologie
  • Roche
  • Royal DSM (part of DPx Holdings)
  • SAFC (part of Sigma-Aldrich)
  • Samsung
  • Samsung Bioepis (part of Samsung)
  • Samsung BioLogics (part of Samsung)
  • Sandoz (part of Novartis)
  • Sanofi
  • Schering-Plough (part of Merck & Co.)
  • SCM Pharma
  • Seattle Genetics
  • ShangPharma
  • SICOR Biotech (part of Teva)
  • Stada Arzneimittel
  • Sunshine Biopharma
  • Takeda
  • TAPI (part of Teva)
  • Teva Pharmaceutical Industries
  • Tonghua Dongbao Pharmaceutical
  • Toyobo Biologics
  • Tufts Center for the Study of Drug Development (CSDD)
  • Vertex
  • Vida Pharma
  • World Health Organization (WHO)
  • WuXi PharmaTech
  • Xcellerex
  • Zhangjiang Biotech and Pharmaceutical Base Development (ZJ Base)
  • Zhejiang Jiang Yuan Tang Biotechnology
  • Zhuhai United Laboratories
Back to Top